Table 1.
Patient demographics.
| Variable | Maintained primary patency at 1-year (n = 49) | Loss of primary patency at 1-year (n = 28) | Log rank p value |
|---|---|---|---|
| Gender | 0.33 | ||
| M | 39 (79.6%) | 25 (89.3%) | |
| F | 10 (20.4%) | 3 (10.7%) | |
| Age | 0.92 | ||
| <55 | 11 (22.9%) | 7 (25%) | |
| >55 | 38 (79.2%) | 21(75%) | |
| Smoker | 0.97 | ||
| Non-smoker | 34 (69.4%) | 19 (67.9%) | |
| Current smoker | 15 (30.6%) | 9 (32.1%) | |
| ASA grade | 0.06 | ||
| 2 | 12 (24.5%) | 11 (39.3%) | |
| 3 | 36 (73.5%) | 15 (53.6%) | |
| 4 | 1 (2%) | 1 (3.6%) | |
| 5 | 0 (0%) | 1 (3.6%) | |
| Diabetes | 22 (44.9%) | 10 (35.7%) | 0.46 |
| HCL | 30 (61.2%) | 13 (46.4%) | 0.13 |
| HTN | 34 (69.4%) | 13 (46.4%) | 0.041* |
| IHD | 24 (49%) | 9 (32.1%) | 0.16 |
| Renal | 5 (10.2%) | 4 (14.3%) | 0.46 |
| Stroke | 4 (8.2%) | 4 (14.3%) | 0.43 |
| DVT | 2 (4.1%) | 2 (7.1%) | 0.65 |
| COPD | 7 (14.3%) | 3 (10.7%) | 0.57 |
| Statin therapy | 45 (91.8%) | 25 (89.3%) | 0.53 |
| Previous ipsilateral revascularisation | 11 (22.4%) | 17 (60.1%) | <0.001* |
| Indication | 0.038* | ||
| Claudication | 14 (28.6%) | 3 (10.7%) | |
| CLTI | 28 (57.1%) | 24 (85.7%) | |
| Aneurysm | 7 (14.3%) | 1 (3.6%) | |
| Runoff score | 0.38 | ||
| <5 | 34 (70.8%) | 22 (81.5%) | |
| >5 | 14 (29.2%) | 5 (18.5) | |
| n=48 | n=27 | ||
| Conduit | 0.47 | ||
| Vein | 40 (81.6%) | 21 (75%) | |
| Prosthetic | 9 (18.4%) | 7 (25%) | |
| Target level | 0.0096* | ||
| AK | 20 (40.8%) | 3 (10.7%) | |
| BK | 29 (59.2%) | 25 (89.3%) | |
| Urgency | 0.76 | ||
| Elective | 37 (75.5%) | 22 (78.6%) | |
| Emergency | 12 (24.5%) | 6 (21.4%) | |
| Antithrombotic strategy | 0.66 | ||
| SAP | 13 (26.5%) | 5 (17.9%) | |
| Anticoagulation | 4 (8.2%) | 2 (7.1%) | |
| Combined | 22 (44.9%) | 13 (46.4%) | |
| DAPT | 10 (20.4%) | 8 (28.6%) |
ASA: American Society of Anesthesiologists; HCL: hypercholesterolaemia; HTN: hypertension; IHD: ischaemic heart disease; DVT: deep vein thrombosis; COPD: chronic obstructive pulmonary disease; CLTI: chronic limb threatening ischaemia; AK: above knee; BK: below knee; SAP: single antiplatelet; Combined: combined antiplatelet and anticoagulation; DAPT: dual antiplatelet therapy.
*
p<0.05.